Nonetheless, the favourable clinical responses seen in the current study can be compared with the disappointing historical studies of CTLA-4 inhibitors, both as single-agents and combined with chemotherapy, in metastatic non-small cell lung cancer [3, 4]. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.